December 2023 in “Journal of ethnopharmacology” Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.
November 2025 in “Journal of Investigative Dermatology” May 1962 in “Zhurnal Fizicheskoi Khimii (U.S.S.R.) For English translation see Russ. J. Phys. Chem. (Engl. Transl.)” PCOS causes hormonal imbalances and health issues like infertility and heart disease.
January 2015 in “Journals & Books Hosting (International Knowledge Sharing Platform)” Compound 1 showed promising anticancer activity.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
November 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
21 citations
,
March 2021 in “Molecules” The new formulation greatly improved quercetin absorption in rats.
22 citations
,
September 1986 in “Journal of Investigative Dermatology” Low-dose topical alpha-terthienyl may be a safer option for treating skin conditions with light therapy.
March 2024 in “Organic letters” A new method efficiently modifies alkenes to create useful medicinal compounds.
60 citations
,
August 2022 in “ESMO Open” Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
13 citations
,
November 2021 in “Frontiers in Molecular Biosciences” Reducing reactive oxygen species can help treat nerve damage from platinum cancer drugs.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
March 2019 in “Journal der Deutschen Dermatologischen Gesellschaft” Rothmund-Thomson syndrome type 2 can cause chronic, poorly healing wounds.
14 citations
,
January 2022 in “Evidence-based Complementary and Alternative Medicine” Cryptotanshinone may help treat postmenopausal osteoporosis and protect kidneys.
31 citations
,
January 1989 in “The Prostate/The prostate” Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.
10 citations
,
July 2022 in “Journal of Medicinal Chemistry” Adding a second method to PROTACs could improve cancer treatment.
63 citations
,
November 2015 in “Pharmaceutical Sciences” Nanophytosomes can improve the delivery and effectiveness of herbal medicines like Rutin.
7 citations
,
April 1979 in “The Journal of Pediatrics” 2 citations
,
June 1985 in “PubMed” Ethylenthiourea is toxic to the liver and nervous system, especially with alcohol.
6 citations
,
May 1986 in “Cancer Chemotherapy and Pharmacology” The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.
24 citations
,
November 2015 in “Frontiers in Genetics” Nitroxide drugs can safely and effectively treat age-related diseases like macular degeneration and cardiovascular issues.
January 2026 in “Dermatologic Therapy” Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.
9 citations
,
October 2025 in “MedComm” PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
53 citations
,
March 2006 in “Biopolymers” TTD hair is brittle due to fewer sulfur amino acids and unstable disulfide bonds.
December 2025 in “Dermatology Reports” Topical ruxolitinib quickly improves non-segmental vitiligo.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
January 2023 in “Cutaneous and Ocular Toxicology”
2 citations
,
July 2007 in “Cancer biology & therapy” Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.